To secure a rapid and sufficient supply of vaccines and medicines, the global south has asked for a waiver of intellectual property rights. But despite the gravity of the situation, that is rejected outright by the EU. That should not come as a surprise. A briefing from CEO outlines the EU's traditional role as a staunch defender of big pharma monopolies, and how the push for provisions on 'data exclusivity' in trade agreements with third countries have seeked to undermine even existing flexibility under international rules.

Chemical giant's lobbyists woo MEPs via online wine tasting, just as the battle over pesticides reduction proposed by the European Green Deal heats up. But does this event comply with existing rules on lobbying gifts and events targeting MEPs?

A detailed summary of the findings and conclusions of two extensive reports on research public-private partnerships in the EU: the Innovative Medicines Initiative (IMI) and the Bio-Based Industries (BBI) Joint Undertakings.

Despite strong calls from MEPs and the public, ExxonMobil and its lobby groups mobilise enough behind-the-scenes pressure to stop the European Parliament taking away its lobby badges

In this special Summer episode we bring you the true story of how the EU has been dealing with the covid-19 pandemic so far and why it seems to have a deep love affair with Big Pharma.

New research by Corporate Europe Observatory shows how a behind-the-scenes Council 'working party' which plays a key role in preparing the positions that member states take in the Council on proposed EU laws and policies is offering privileged access to corporate interests.

A secretive Council working party allows corporate lobbyists to influence policy positions. New research by Corporate Europe Observatory into this little scrutinised channel shows how business priorities – such as demands for deregulation – are given a privileged hearing by officials whilst public interest voices are shut out.

The European Commission said it wants to avoid giving billions in bailouts to the fossil fuel industry like it did in 2008 - but it’s doing just that: In Italy, France, Portugal and the Spanish State, €8.3 billion of EU recovery funds will be spent on hydrogen and renewable gases, thanks to fierce industry lobbying at national and EU level.

A new scientific analysis (1) concludes that the European Food Safety Authority's (EFSA) claim that glyphosate is not genotoxic cannot be justified on the basis of manufacturers’ studies. Of the 53 industry-funded studies used for the EU’s current authorization of glyphosate, 34 were identified as "not reliable", 17 as "partly reliable" and only 2 studies as "reliable" from a methodological point of view.

The glyphosate battle is back. A new scientific analysis finds that most of industry’s studies provided to EU authorities to prove glyphosate’s safety, did not meet basic international scientific standards as set by the OECD. This comes at a moment when the European Food Safety Authority (EFSA) is about to start its re-assessment of glyphosate, a key ingredient of the infamous weed killer Roundup.